A biopharmaceutical company developing monoclonal
antibody products through use of a proprietary humanantibody technology

Morphotek Overview•

Antibody-focused biopharmaceutical company•

founded in 2000, based on a genome evolution technology called morphogenics



developing fully human antibodies through unique process patents



applying validated technology to internal pipeline and partnerships

Company focus and value creation•

clinical validation of therapeutic antibody pipelineleveraging antibody technology in development partnerships with leading research
institutes studying cancer, inflammation and infectious diseases

Strong scientific and clinical expertise in biologics and oncology•

2 clinical-stage compounds (MORAb-003 and MORAb-009)

multiple preclinical compounds positioned for new Investigational New Drugs (IND)

Strong IP position on technology and products

2

8 issued patents, >50 under active prosecutionsignificant barrier to entry - many patents extend past 2020

Morphotek Businessleverage technology with collaborations for product development
lead clinical products

MORAb-003-ovarian cancer• other cancers: lung, breast, colon cancer• Ph1-Memorial Sloan Kettering• Ph2- multi-centered

MORAb-009-pancreatic cancer• other cancers: lung, mesothelioma• Johns Hopkins, Fox Chase, National Cancer Insttargets accessed from collaborations

product pipeline•MORAb-004-neovascular disease•MORAb-022-inflammatory disease•MORAb-028-metastatic melanoma•MORAb-047-infectious disease•MORAb-048-infectious diseasetechnology for discovery/products
human antibody discovery technology
immunize withdisease antigen

highhigh-titer cell lines
30

HumanHybridoma

pg/cell/day

25
20
15
105morphogenics

0parental

human B-cell

MORPHODOMAMORPHODOMAcell Linehighhigh-affinity MAbs

myeloma cell

310-10affinity ( nM)) )Affinity( nM

antibody/cell line
optimization

5X10 -810-7
parentalparental

MORPHODOMAMORPHODOMA

antibody

MORPHODOMAMORPHODOMAProprietary Antibody Technology
Integration of technology to support product development
gene discovery

patient analysis
mAb libraries for target
discovery & rapid mAbdevelopment¾Morphotek collaborators¾ In-licensed targets

human
antibody
libraries¾ Oncology¾ Infectious disease¾ Inflammatory disease¾ Neurological disease

whole cell discovery
4

support company
wide clinical trials

Diagnostic reagents&Therapeutic leads

clinicaldevelopment

product development

MORPHODOMA® Technology
optimizing human antibodies and production lines via wholegenome evolution (morphogenics)

DISCOVERYOPTIMIZATION

antibody
producing cell

antibody/cell line
optimization

FINAL PRODUCT-GMP manufacturinghigh-titer cell lines
30
2520
1510

morphogenics

50parent

MORPH

MORPH

cell Linederived from:patient lymphocytes
immunized B-cells

whole genomeevolution
geneduplication
NaturalMismatch repair
identical offspring-therapeutic efficacyhigh-affinity antibodies
10-10cell divisionnatural occurring
genetic mutations

5X10-8
Mismatch repair

Morphogenics

geneduplication

diverse offspringcell division

10-7

parentalparent

MORPH

antibody

5

MORPH

MORPHODOMA® Derived Products
Robust pipeline…
Antibody

1st Indication

Other
indications

Description

Collaborator

Stage

MORAb-003

Ovarian cancer

Breast, CRC,
NSCLC, Renal

antigen on >90%
ovarian tumors

Memorial Sloan
KetteringPH1/PH2

MORAb-009

Pancreatic &lung cancer

CRC, Ovarian

antigen on 100%
pancreatic tumors

Johns
Hopkins/NCI

PH1

MORAb-004NeovasculardiseaseCancer, ADM,DR

antigen on 100%
tumor endothelia

Johns Hopkins/

PC

Rheumatoid

Asthma, MS,Psoriasis

cytokine involved inRA in mouse models

LudwigPC

MORAb-022

arthritis

6John Wayne

MORAb-028

Metastaticmelanoma

Brain, SCLC

Human mAb withclinical activity
melanomaJohn Wayne
Cancer InstitutePC

MORAb-047

Infectious
disease

Biodefense

Antigen produced bypathogenic microbes

USAMRIIDPC

MORAb-048

Infectious
disease

Biodefense

Antigen produced bypathogenic microbes

USAMRIIDPC

Post Merger Winning Formulaglobal biologics efforts to develop disease-specific drugs
global reach of new
biologic therapies+

Global discovery capability
Product development expertise
Commercialization engine &Marketing muscle

7=

Novel targets
Proprietary antibody technologies
Biologics development know-how

Therapeutic antibodies and proteinsto specifically treat root cause ofhuman diseases